SynthesisDrug design, development and therapy2020
An Updated Systematic Review With Meta-Analysis Of Randomized Trials On Topical Cyclosporin A For Dry-Eye Disease.
Synthesis in Drug design, development and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Pooled it
- Evidence on the Use of Topical Ciclosporin for Ocular Surface Disease: A Systematic Review and Meta-Analysis.Clinical & experimental ophthalmology · 2025Pooled it
- Efficacy of topical cyclosporine A in optimizing ocular surface and relieving dry eye symptoms after cataract surgery: a systematic review and meta-analysis of randomized controlled trials.International ophthalmology · 2025Pooled it
- The efficacy and safety of varenicline nasal spray for the management of dry eye signs: a systematic review and meta-analysis.BMC ophthalmology · 2023Pooled it
- Aqueous-deficient dry eye disease: Preferred practice pattern guidelines on clinical approach, diagnosis, and management.Indian journal of ophthalmology · 2023Guideline
- Comparison of seven cyclosporine A formulations for dry eye disease: A systematic review and network meta-analysis.Frontiers in pharmacology · 2022Pooled it
- The effect of 0.1% topical ciclosporin a for 12-weeks on the ocular surface innate and adaptive immune response in dry eye disease: protocol for a randomized controlled clinical trial.Annals of medicine · 2026Article
- A National Survey Including Data from 5986 Dry Eyes Treated with a Novel Tear Substitute Containing Ribohyal.Journal of clinical medicine · 2026Article
- Cyclosporine A in the treatment of dry eye syndrome in patients with Sjögren's disease-a systematic review.EULAR rheumatology open · 2025Article
- Characterization of Individuals with High-Frequency Artificial Tear Supplement Use.Journal of clinical medicine · 2025Article
- Impact of dry eye disease treatment on patient quality of life.Frontiers in medicine · 2024Review
- Interventions for Dry Eye: An Overview of Systematic Reviews.JAMA ophthalmology · 2024Article
- The Efficacy and Safety of Rebamipide Ophthalmic Suspension (OPC-12759) in Patients with Dry Eye Disease: A Systematic Review of Randomized Controlled Trials.Journal of clinical medicine · 2023Review
- Treatment of Dry Eye Disease (DED) in Asia: Strategies for Short Tear Film Breakup Time-Type DED.Pharmaceutics · 2023Review
- Management of inflammation in dry eye disease: Recommendations from a European panel of experts.European journal of ophthalmology · 2023Review
- Effectiveness of Topical Cyclosporin-A 0.1% Compared to Combined Topical Cyclosporin-A 0.1% with Topical Sodium Hyaluronate on Interleukin-6 Levels in the Tears of Patients with Dry Eye Disease.Vision (Basel, Switzerland) · 2023Article
- Efficacy of Topical Administration of Corticosteroids for the Management of Dry Eye Disease: Systematic Review and Meta-Analysis.Life (Basel, Switzerland) · 2022Review
- OC-01 (Varenicline Solution) Nasal Spray Demonstrates Consistency of Effect Regardless of Age, Race, Ethnicity, and Artificial Tear Use.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Recommendations for Off-Label Drug Use in Ophthalmology in China: A Clinical Practice Guideline.Frontiers in pharmacology · 2022Article
- Tolerability and Optimal Therapeutic Dosage of Clomipramine for Premature Ejaculation: A Systematic Review and Meta-Analysis.Sexual medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsTo evaluate the effects of topical cyclosporin A (CsA) and artificial tears (ATs) for treating patients with dry-eye disease (DED).
methodsOn January 25, 2019, five electronic databases and reference lists were searched for randomized clinical trials (RCTs) comparing CsA with ATs among patients with DED. The search strategy had no restriction on language or time. Two authors extracted surgery, mean age, anesthesia for Schirmer's test, tear-breakup time, Schirmer's test score, fluorescein-staining score, ocular surface-disease index, and adverse events. Mean differences (MDs) were calculated for continuous outcomes and Peto ORs for dichotomous data with zero cells. Results were analyzed with 95% CIs in a random-effect model.
resultsEleven RCTs recruiting 1,085 cases with DED were included. Pooled results showed that CsA had better tear-breakup time (MD 0.94, 95% CI 0.08-1.80), fluorescein-staining score (standardized MD -0.72, 95% CI -1.28 to -0.16), and ocular surface-disease index (MD -4.75, 95% CI -6.31 to -3.18) when compared to ATs. Although CsA had more adverse events than ATs (Peto OR 7.70, 95% CI 3.17-18.68), no serious adverse events were reported.
conclusionOverall, CsA is an effective option for treating patients with DED, yet our evidence indicated decreasing effects when CsA was combined with ATs. CsA may be worth suggesting to relatively older patients with DED. We anticipate further RCTs to explore the effects of treatment duration, optimal dosage, and efficacy of CsA in different DED etiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.